Ted Yednock Sells 4,500 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) EVP Ted Yednock sold 4,500 shares of the firm’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $7.10, for a total value of $31,950.00. Following the transaction, the executive vice president now directly owns 71,365 shares of the company’s stock, valued at $506,691.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Ted Yednock also recently made the following trade(s):

• On Thursday, September 5th, Ted Yednock sold 5,500 shares of Annexon stock. The shares were sold at an average price of $5.64, for a total value of $31,020.00.
• On Thursday, August 29th, Ted Yednock sold 5,500 shares of Annexon stock. The stock was sold at an average price of $5.95, for a total value of $32,725.00.

Annexon Stock Performance

Annexon stock opened at $7.03 on Friday. The stock has a market capitalization of $649.66 million, a price-to-earnings ratio of -4.78 and a beta of 1.28. Annexon, Inc. has a 52-week low of $1.57 and a 52-week high of $8.40. The stock’s 50 day moving average price is $6.05 and its two-hundred day moving average price is $5.58.

Annexon (NASDAQ:ANNX) last issued its earnings results on Monday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.23). On average, equities research analysts forecast that Annexon, Inc. will post -0.97 EPS for the current year.

Analysts Set New Price Targets

ANNX has been the subject of several analyst reports. Needham & Company LLC restated a “buy” rating and set a $16.00 price target on shares of Annexon in a report on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research report on Monday, September 9th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Annexon in a report on Tuesday, August 13th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $15.80.

Institutional Trading of Annexon

Several large investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. raised its stake in Annexon by 78.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock worth $48,000 after buying an additional 2,949 shares during the period. Comerica Bank acquired a new position in shares of Annexon during the first quarter worth approximately $72,000. Sandia Investment Management LP acquired a new position in shares of Annexon during the second quarter worth approximately $49,000. Victory Capital Management Inc. bought a new position in shares of Annexon in the 2nd quarter worth $51,000. Finally, Principal Financial Group Inc. acquired a new stake in Annexon in the 2nd quarter valued at $56,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.